Pharm-Olam, LLC (“Pharm-Olam” or the “Company”) is an award-winning contract research organization (“CRO”). Headquartered in Houston, Texas, the Company operates on a global scale with 25 offices servicing over 60 countries. In addition to global full-service offerings, the Company also offers regional service solutions from North America, Europe and India. Pharm-Olam conducts global and local clinical trials in all major markets of the world, from Phase I studies with unique populations to large multi-national Phase III-IV trials.
Pharm-Olam was evaluating different strategies to enhance its financial flexibility in order to access additional capital to support its growth strategies as it continues to enhance their services in the company’s five core therapeutic areas: oncology-hematology, infectious disease and vaccines, autoimmune, allergy and rare disease.
Pharm-Olam worked with its existing stakeholders and developed a change in ownership transaction that would be seamless to day-to-day operations and enhance the company’s capital structure. SSG was retained by Pharm-Olam to complete a comprehensive valuation analysis to determine an estimated enterprise value of the Company. The valuation was used as support the proposed change in ownership transaction. Operating within a compressed timeframe, SSG was able to complete a thorough due diligence review of the Company and prepare a detailed valuation report within two weeks of being engaged. With the valuation analysis complete, the Company was able to consummate the transaction and properly capitalize the business for future success.